ORXs Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 30.95 |
| 52 Week High | SEK 33.24 |
| 52 Week Low | SEK 18.68 |
| Beta | 0.93 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -53.25% |
| 5 Year Change | -30.76% |
| Change since IPO | -77.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORXs | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | -2.2% |
| 1Y | n/a | -3.5% | 2.4% |
Return vs Industry: Insufficient data to determine how ORXs performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORXs performed against the UK Market.
Price Volatility
| ORXs volatility | |
|---|---|
| ORXs Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ORXs has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORXs's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 126 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company’s development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain.
Orexo AB (publ) Fundamentals Summary
| ORXs fundamental statistics | |
|---|---|
| Market cap | SEK 635.80m |
| Earnings (TTM) | -SEK 151.70m |
| Revenue (TTM) | SEK 612.30m |
1.0x
P/S Ratio-4.2x
P/E RatioIs ORXs overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORXs income statement (TTM) | |
|---|---|
| Revenue | SEK 612.30m |
| Cost of Revenue | SEK 97.00m |
| Gross Profit | SEK 515.30m |
| Other Expenses | SEK 667.00m |
| Earnings | -SEK 151.70m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Jan 26, 2023
| Earnings per share (EPS) | -4.41 |
| Gross Margin | 84.16% |
| Net Profit Margin | -24.78% |
| Debt/Equity Ratio | 165.6% |
How did ORXs perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/14 19:34 |
| End of Day Share Price | 2022/08/17 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orexo AB (publ) is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Klas Palin | Carnegie Commissioned Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |